Inactive Instrument

Satsuma Pharmaceuticals, Inc.

STSA

US80405P1075

Biotechnology & Medical Research

Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index

June 09, 2023 at 12:00 am EDT

Latest news about Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	Jan. 17	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index	23-06-09	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index	23-06-09	CI
Insider Buy: Satsuma Pharmaceuticals	23-06-08	MT
Satsuma Pharmaceuticals, Inc. Announces CFO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces CEO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces Board Changes	23-06-08	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review	23-05-18	MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101	23-05-18	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
North American Morning Briefing : Sentiment -3-	23-04-19	DJ
HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy	23-04-18	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Sector Update: Health Care Stocks Higher Premarket Monday	23-04-17	MT
Bank Earnings in Focus as US Equity Futures Tread Water	23-04-17	MT
Top Premarket Gainers	23-04-17	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	23-04-17	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	23-04-16	CI
Satsuma Pharmaceuticals Cash, Cash Equivalents and Marketable Securities Almost Halve to $52.5 Million at End of 2022	23-03-28	MT
Satsuma Pharmaceuticals Implements 36% Reduction in Workforce as Part of Cost-Cutting Program Shares Fall After Hours	23-03-28	MT
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-27	CI
North American Morning Briefing : Stock Futures -3-	23-03-27	DJ

Chart Satsuma Pharmaceuticals, Inc.

Duration

Period

More charts

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs